I have a bit of information about that.
What I understand from that situation is that this drug was for export only when they discovered a problem with it. It wasn't a drug that was used within Canada. So that company is making products that go outside Canada, when maybe a priority should be on getting drugs for Canadians, if they're manufactured in Canada.
I don't have a whole lot more information on that.
To your earlier point that while mandatory reporting could be a viable option—and I'm not totally sold that it has to be mandatory, but I might be able to be convinced—the other part of that is really the sole-sourcing issue. If you have competition and you have multiple sites, if one site comes under attack, it doesn't make sense from a practical point of view to have one source for anything.